Mirati Therapeutics, Inc. (MRTX) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Total revenue	12.4	72.1	13.4	3.3	12.9
Total revenue growth	-82.7%	438.1%	301.7%	-74.2%
Revenue
Total revenue	12.4	72.1	13.4	3.3	12.9
Total revenue growth	-82.7%	438.1%	301.7%	-74.2%
Operating expenses
Cost of product revenue	0.6
Research and development	531.6	508.6	299.3	182.9	93.9	58.1	68.5	49.0
Selling, general and administrative	239.8	136.7	83.4
Total operating expenses	772.0	645.3	382.8	225.4	115.6	71.5	83.8	64.7
Loss from operations	-759.6	-573.2	-369.4	-222.1	-102.6	-71.5	-83.8	-64.7
Operating margin	-6108.0%	-795.1%	-2756.9%	-6659.8%	-794.0%
Other income (expense), net	19.2	-5.3	11.4	8.8	4.2	1.1	0.7	0.2
Net loss	-740.9	-581.8	-357.9	-213.3	-98.4	-70.4	-83.1	-64.5
Foreign currency translation adjustment	-9.6
Comprehensive loss	-753.7	-582.5	-358.1	-212.8	-98.4	-70.5	-83.1	-64.5

Basic net loss per share (USD per share)	($13.18)	($11.21)	($7.96)	($5.69)	($3.19)	($2.78)	($4.20)	($3.82)
Diluted net loss per share (USD per share)	($13.18)	($11.21)	($7.96)	($5.69)	($3.19)	($2.78)	($4.20)	($3.82)

Weighted average common shares outstanding, basic (shares)	56.2	51.9	45.0	37.5	30.9	25.3	19.8	16.9
Weighted average common shares outstanding, diluted (shares)	56.2	51.9	45.0	37.5	30.9	25.3	19.8	16.9